数据
资源
版本对比
免费注册
预约演示
免费注册
Phathom Pharmaceuticals
to Participate in the 23rd Annual Needham Virtual Healthcare Conference
2024-04-03
·
BioSpace
引进/卖出
上市批准
FLORHAM PARK, N.J., April 03, 2024 (GLOBE NEWSWIRE) --
Phathom Pharmaceuticals, Inc.
(Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for
gastrointestinal diseases
, announced today that members of the management team will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 9:30 a.m. ET. Company management will also participate in one-on-one meetings during the conference, which will run from April 8-11, 2024. To access the live webcast and an archived recording of the event, visit the News & Events section of the
Phathom
website at . Recordings will be available for 90 days following the conclusion of the meeting. About
Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals
is a biopharmaceutical company focused on the development and commercialization of novel treatments for
gastrointestinal diseases
.
Phathom
has in-licensed the exclusive rights to
vonoprazan
, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as
VOQUEZNA
® (
vonoprazan
) tablets for the treatment of
Erosive GERD
and relief of related
heartburn
in adults, in addition to
VOQUEZNA
® TRIPLE PAK® (
vonoprazan
tablets, amoxicillin capsules,
clarithromycin
tablets) and
VOQUEZNA
® DUAL PAK® (
vonoprazan
tablets, amoxicillin capsules) for the treatment of
H. pylori infection
in adults. For more information about
Phathom
, visit the company’s website at and follow on LinkedIn and X. MEDIA CONTACT Nick Benedetto 1-877-742-8466 media@phathompharma.com INVESTOR CONTACT Eric Sciorilli 1-877-742-8466 ir@phathompharma.com © 2024
Phathom Pharmaceuticals
. All rights reserved.
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Phathom Pharmaceuticals, Inc.
适应症
胃肠道疾病
胃食管反流
胃灼热
[+1]
靶点
-
药物
富马酸伏诺拉生
克拉霉素
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
第一三共ADC药物DS-8201专利调研实务指南
智慧芽生物医药
2024年3月全球首批及特殊审评药物报告
智慧芽生物医药
THR-β 激动剂药物进展及专利调研报告
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务